22nd Century Group Inc. (XXII)
Market Closed
15 Oct, 08:00 PM
NASDAQ (CM) NASDAQ (CM) Primary $
0. 63
-0.02
-3.5967%
Pre Market
$
+0.02 +3.6352% 0. 65
300.5K Market Cap
- P/E Ratio
- Div Yield
1.15M Volume
-6.88 Eps
$ 0.65
Previous Close Investors:
Want to track XXII and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
XXII closed today lower at $0.63, a decrease of -3.5967% from yesterday's close, completing a monthly decrease of -80.2767% or -$2.55. Over the past 12 months, XXII stock lost -22.087%.
XXII is not paying dividends to its shareholders.
The last earnings report, released on May 11, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.8539%, based on the last three reports.
22nd Century Group Inc. has completed 7 stock splits, with the recent split occurring on Jun 12, 2026.
The company's stock is traded on one exchange.
22nd Century Group, Inc. (XXII) Q2 2026 Earnings Call Prepared Remarks Transcript
22nd Century Group, Inc. (XXII) Q2 2026 Earnings Call Prepared Remarks Transcript
Seekingalpha | 2 months ago
22nd Century Group, Inc. (XXII) Q1 2026 Earnings Call Prepared Remarks Transcript
22nd Century Group, Inc. (XXII) Q1 2026 Earnings Call Prepared Remarks Transcript
Seekingalpha | 5 months ago
22nd Century Group, Inc. (XXII) Q4 2025 Earnings Call Prepared Remarks Transcript
22nd Century Group, Inc. (XXII) Q4 2025 Earnings Call Prepared Remarks Transcript
Seekingalpha | 6 months ago
22nd Century Group Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1 | $8.04 | $0.63 | -$7.41 | -92.16% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 1 | $6.14 | $0.63 | -$5.51 | -89.74% |
 Christopher C. Powers Farther Finance Advisors, LLC | 2 | $12.28 | $1.25 | -$11.03 | -89.82% |
 Stephen A. Greco Pandora Wealth Inc. | 0.01 | $1.54 | - | -$1.54 | -100% |
 Kilter Group LLC Kilter Group LLC | 1 | $6.14 | $0.63 | -$5.51 | -89.74% |
22nd Century Group Inc. (XXII) FAQ
What is the stock price today?
The current price is $0.63.
On which exchange is it traded?
22nd Century Group Inc. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is XXII.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 300.5K.
Has 22nd Century Group Inc. ever had a stock split?
22nd Century Group Inc. had 7 splits and the recent split was on Jun 12, 2026.
22nd Century Group Inc. Profile
| Tobacco Industry | Consumer Staples Sector | Lawrence D. Firestone CEO | NASDAQ (CM) Exchange | 90137F707 CUSIP |
| US Country | 32 Employees | - Last Dividend | 12 Jun 2026 Last Split | 26 Jan 2011 IPO Date |
Overview
22nd Century Group, Inc. is a pioneering company in the field of agricultural biotechnology, concentrating its efforts on tobacco harm reduction and the advancement of health and wellness through innovative plant science. This involves the development of reduced nicotine tobacco products and leveraging plant biotechnology for life science and consumer product advancements. Founded in 1998 and based in Buffalo, New York, the company engages in scientific research to achieve its objectives, including collaborations aimed at enhancing the properties of hemp and cannabis for both medical and agricultural applications.
Products and Services
- VLN King & VLN Menthol King Cigarettes: These products represent the company’s forefront innovation, characterized by their very low nicotine content. Tailored to address the public health concern regarding nicotine addiction, these cigarettes aim at providing a safer alternative for smokers. The VLN King and VLN Menthol King are designed not only to reduce smokers' nicotine consumption but also to potentially aid in smoking cessation efforts.
- SPECTRUM Research Cigarettes: Specially developed for use in independent clinical studies, SPECTRUM research cigarettes serve an important role in tobacco research. They are utilized by scientists and health professionals to investigate the impact of nicotine and other tobacco product constituents on health, behavior, and genetics. By providing a controlled product for clinical research, 22nd Century Group, Inc. significantly contributes to advances in public health knowledge regarding tobacco use.
- Hemp/Cannabis Plant Development: In collaboration with Keygene N.V., 22nd Century Group, Inc. is also making strides in the development of hemp and cannabis plants with enhanced cannabinoid profiles and agronomic traits. This initiative aims to leverage plant biotechnology for medical, therapeutic, and agricultural purposes, offering potentially revolutionary applications in these fields. The effort underscores the company’s commitment to utilizing advanced biotechnologies to improve the quality and functionality of plant-derived products.
Contact Information
Address: 321 Farmington Road
Phone: 716 270 1523
Website: https://www.xxiicentury.com
2026 © Marketlog. All Rights Reserved.
